Eversept Partners, LP Amarin Corp Plcuk Call Options Transaction History

Eversept Partners, LP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2021 Nov 08, 2023	SELL	$5.03 - $8.8 $4.25 Million - $7.43 Million	-844,600 Reduced 65.71%	440,800 $2.74 Million
Q4 2020 Nov 08, 2023	BUY	$4.04 - $5.31 $5.19 Million - $6.83 Million	1,285,400 New	1,285,400 $6.29 Million
Q3 2020 Nov 08, 2023	BUY	$3.64 - $7.76 $669,032 - $1.43 Million	183,800 Added 17.01%	1,264,100 $5.32 Million
Q2 2020 Nov 08, 2023	BUY	$4.78 - $8.26 $271,026 - $468,342	56,700 Added 5.54%	1,080,300 $7.48 Million
Q1 2020 Nov 08, 2023	BUY	$4.0 - $21.53 $117,600 - $632,982	29,400 Added 2.96%	1,023,600 $4.09 Million
Q4 2019 Nov 08, 2023	BUY	$13.94 - $24.12 $11.6 Million - $20.1 Million	833,100 Added 517.13%	994,200 $21.3 Million
Q3 2019 Nov 08, 2023	BUY	$13.89 - $23.16 $2.24 Million - $3.73 Million	161,100 New	161,100 $2.44 Million

3.85M

Ticker AMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 403,206,016
Market Cap $6.01B
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Eversept Partners, LP with notifications on news.